Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model

Sara E. Gombash, Jack W. Lipton, Timothy J. Collier, Lalitha Madhavan, Kathy Steece-Collier, Allyson Cole-Strauss, Brian T. Terpstra, Anne L. Spieles-Engemann, Brian F. Daley, Susan L. Wohlgenant, Valerie B. Thompson, Fredric P. Manfredsson, Ronald J. Mandel, Caryl E. Sortwell

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Neurotrophic factors are integrally involved in the development of the nigrostriatal system and in combination with gene therapy, possess great therapeutic potential for Parkinson's disease (PD). Pleiotrophin (PTN) is involved in the development, maintenance, and repair of the nigrostriatal dopamine (DA) system. The present study examined the ability of striatal PTN overexpression, delivered via psueudotyped recombinant adeno-associated virus type 2/1 (rAAV2/1), to provide neuroprotection and functional restoration from 6-hydroxydopamine (6-OHDA). Striatal PTN overexpression led to significant neuroprotection of tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc) and THir neurite density in the striatum, with long-term PTN overexpression producing recovery from 6-OHDA-induced deficits in contralateral forelimb use. Transduced striatal PTN levels were increased threefold compared to adult striatal PTN expression and approximated peak endogenous developmental levels (P1). rAAV2/1 vector exclusively transduced neurons within the striatum and SNpc with approximately half the total striatal volume routinely transduced using our injection parameters. Our results indicate that striatal PTN overexpression can provide neuroprotection for the 6-OHDA lesioned nigrostriatal system based upon morphological and functional measures and that striatal PTN levels similar in magnitude to those expressed in the striatum during development are sufficient to provide neuroprotection from Parkinsonian insult.

Original languageEnglish (US)
Pages (from-to)544-554
Number of pages11
JournalMolecular Therapy
Volume20
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Corpus Striatum
Oxidopamine
Dependovirus
Tyrosine 3-Monooxygenase
Neurons
Forelimb
pleiotrophin
Neuroprotection
Nerve Growth Factors
Neurites
Genetic Therapy
Parkinson Disease
Dopamine
Maintenance
Injections

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Gombash, S. E., Lipton, J. W., Collier, T. J., Madhavan, L., Steece-Collier, K., Cole-Strauss, A., ... Sortwell, C. E. (2012). Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Molecular Therapy, 20(3), 544-554. https://doi.org/10.1038/mt.2011.216

Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. / Gombash, Sara E.; Lipton, Jack W.; Collier, Timothy J.; Madhavan, Lalitha; Steece-Collier, Kathy; Cole-Strauss, Allyson; Terpstra, Brian T.; Spieles-Engemann, Anne L.; Daley, Brian F.; Wohlgenant, Susan L.; Thompson, Valerie B.; Manfredsson, Fredric P.; Mandel, Ronald J.; Sortwell, Caryl E.

In: Molecular Therapy, Vol. 20, No. 3, 03.2012, p. 544-554.

Research output: Contribution to journalArticle

Gombash, SE, Lipton, JW, Collier, TJ, Madhavan, L, Steece-Collier, K, Cole-Strauss, A, Terpstra, BT, Spieles-Engemann, AL, Daley, BF, Wohlgenant, SL, Thompson, VB, Manfredsson, FP, Mandel, RJ & Sortwell, CE 2012, 'Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model', Molecular Therapy, vol. 20, no. 3, pp. 544-554. https://doi.org/10.1038/mt.2011.216
Gombash, Sara E. ; Lipton, Jack W. ; Collier, Timothy J. ; Madhavan, Lalitha ; Steece-Collier, Kathy ; Cole-Strauss, Allyson ; Terpstra, Brian T. ; Spieles-Engemann, Anne L. ; Daley, Brian F. ; Wohlgenant, Susan L. ; Thompson, Valerie B. ; Manfredsson, Fredric P. ; Mandel, Ronald J. ; Sortwell, Caryl E. / Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. In: Molecular Therapy. 2012 ; Vol. 20, No. 3. pp. 544-554.
@article{c81b1a30e889427cb76691b89f53e42d,
title = "Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model",
abstract = "Neurotrophic factors are integrally involved in the development of the nigrostriatal system and in combination with gene therapy, possess great therapeutic potential for Parkinson's disease (PD). Pleiotrophin (PTN) is involved in the development, maintenance, and repair of the nigrostriatal dopamine (DA) system. The present study examined the ability of striatal PTN overexpression, delivered via psueudotyped recombinant adeno-associated virus type 2/1 (rAAV2/1), to provide neuroprotection and functional restoration from 6-hydroxydopamine (6-OHDA). Striatal PTN overexpression led to significant neuroprotection of tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc) and THir neurite density in the striatum, with long-term PTN overexpression producing recovery from 6-OHDA-induced deficits in contralateral forelimb use. Transduced striatal PTN levels were increased threefold compared to adult striatal PTN expression and approximated peak endogenous developmental levels (P1). rAAV2/1 vector exclusively transduced neurons within the striatum and SNpc with approximately half the total striatal volume routinely transduced using our injection parameters. Our results indicate that striatal PTN overexpression can provide neuroprotection for the 6-OHDA lesioned nigrostriatal system based upon morphological and functional measures and that striatal PTN levels similar in magnitude to those expressed in the striatum during development are sufficient to provide neuroprotection from Parkinsonian insult.",
author = "Gombash, {Sara E.} and Lipton, {Jack W.} and Collier, {Timothy J.} and Lalitha Madhavan and Kathy Steece-Collier and Allyson Cole-Strauss and Terpstra, {Brian T.} and Spieles-Engemann, {Anne L.} and Daley, {Brian F.} and Wohlgenant, {Susan L.} and Thompson, {Valerie B.} and Manfredsson, {Fredric P.} and Mandel, {Ronald J.} and Sortwell, {Caryl E.}",
year = "2012",
month = "3",
doi = "10.1038/mt.2011.216",
language = "English (US)",
volume = "20",
pages = "544--554",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model

AU - Gombash, Sara E.

AU - Lipton, Jack W.

AU - Collier, Timothy J.

AU - Madhavan, Lalitha

AU - Steece-Collier, Kathy

AU - Cole-Strauss, Allyson

AU - Terpstra, Brian T.

AU - Spieles-Engemann, Anne L.

AU - Daley, Brian F.

AU - Wohlgenant, Susan L.

AU - Thompson, Valerie B.

AU - Manfredsson, Fredric P.

AU - Mandel, Ronald J.

AU - Sortwell, Caryl E.

PY - 2012/3

Y1 - 2012/3

N2 - Neurotrophic factors are integrally involved in the development of the nigrostriatal system and in combination with gene therapy, possess great therapeutic potential for Parkinson's disease (PD). Pleiotrophin (PTN) is involved in the development, maintenance, and repair of the nigrostriatal dopamine (DA) system. The present study examined the ability of striatal PTN overexpression, delivered via psueudotyped recombinant adeno-associated virus type 2/1 (rAAV2/1), to provide neuroprotection and functional restoration from 6-hydroxydopamine (6-OHDA). Striatal PTN overexpression led to significant neuroprotection of tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc) and THir neurite density in the striatum, with long-term PTN overexpression producing recovery from 6-OHDA-induced deficits in contralateral forelimb use. Transduced striatal PTN levels were increased threefold compared to adult striatal PTN expression and approximated peak endogenous developmental levels (P1). rAAV2/1 vector exclusively transduced neurons within the striatum and SNpc with approximately half the total striatal volume routinely transduced using our injection parameters. Our results indicate that striatal PTN overexpression can provide neuroprotection for the 6-OHDA lesioned nigrostriatal system based upon morphological and functional measures and that striatal PTN levels similar in magnitude to those expressed in the striatum during development are sufficient to provide neuroprotection from Parkinsonian insult.

AB - Neurotrophic factors are integrally involved in the development of the nigrostriatal system and in combination with gene therapy, possess great therapeutic potential for Parkinson's disease (PD). Pleiotrophin (PTN) is involved in the development, maintenance, and repair of the nigrostriatal dopamine (DA) system. The present study examined the ability of striatal PTN overexpression, delivered via psueudotyped recombinant adeno-associated virus type 2/1 (rAAV2/1), to provide neuroprotection and functional restoration from 6-hydroxydopamine (6-OHDA). Striatal PTN overexpression led to significant neuroprotection of tyrosine hydroxylase immunoreactive (THir) neurons in the substantia nigra pars compacta (SNpc) and THir neurite density in the striatum, with long-term PTN overexpression producing recovery from 6-OHDA-induced deficits in contralateral forelimb use. Transduced striatal PTN levels were increased threefold compared to adult striatal PTN expression and approximated peak endogenous developmental levels (P1). rAAV2/1 vector exclusively transduced neurons within the striatum and SNpc with approximately half the total striatal volume routinely transduced using our injection parameters. Our results indicate that striatal PTN overexpression can provide neuroprotection for the 6-OHDA lesioned nigrostriatal system based upon morphological and functional measures and that striatal PTN levels similar in magnitude to those expressed in the striatum during development are sufficient to provide neuroprotection from Parkinsonian insult.

UR - http://www.scopus.com/inward/record.url?scp=84857787470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857787470&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.216

DO - 10.1038/mt.2011.216

M3 - Article

C2 - 22008908

AN - SCOPUS:84857787470

VL - 20

SP - 544

EP - 554

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -